2. Academic Validation
  3. Antihypertensive action of allantoin in animals

Antihypertensive action of allantoin in animals

  • Biomed Res Int. 2014;2014:690135. doi: 10.1155/2014/690135.
Mei-Fen Chen 1,  Jo-Ting Tsai 2,  Li-Jen Chen 3,  Tung-Pi Wu 4,  Jia-Jang Yang 5,  Li-Te Yin 5,  Yu-Lin Yang 5,  Tai-An Chiang 5,  Han-Lin Lu 6,  Ming-Chang Wu 7
Affiliations

Affiliations

  • 1 Department of Food Science, National Pingtung University of Science and Technology, Neipu, Pingtung City 91201, Taiwan ; College of Medicine and Life Science, Chung Hwa University of Medical Technology, Rende District, Tainan City 71703, Taiwan.
  • 2 Department of Radiation Oncology, Taipei Medical University-Shuang Ho Hospital, and College of Medicine, Taipei Medical University, Taipei City 10361, Taiwan.
  • 3 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan.
  • 4 Department of Obs/Gyn, Tainan SinLau Hospital, The Presbyterian Church in Taiwan, Tainan City 70142, Taiwan.
  • 5 College of Medicine and Life Science, Chung Hwa University of Medical Technology, Rende District, Tainan City 71703, Taiwan.
  • 6 Department of Chinese Medicine, Tainan SinLau Hospital, The Presbyterian Church in Taiwan, Tainan City 70142, Taiwan.
  • 7 Department of Food Science, National Pingtung University of Science and Technology, Neipu, Pingtung City 91201, Taiwan.
PMID: 24745022 DOI: 10.1155/2014/690135
Abstract

The agonists of imidazoline I-1 receptors (I-1R) are widely used to lower blood pressure. It has been indicated that guanidinium derivatives show an ability to activate imidazoline receptors. Also, allantoin has a chemical stricture similar to guanidinium derivatives. Thus, it is of special interest to characterize the effect of allantoin on I-1R. In conscious male spontaneous hypertensive rats (SHRs), mean blood pressure (MBP) was recorded using the tail-cuff method. Furthermore, the hemodynamic analyses in catheterized rats were applied to measure the actions of allantoin in vivo. Allantoin decreased blood pressures in SHRs at 30 minutes, as the most effective time. Also, this antihypertensive action was shown in a dose-dependent manner from SHRs treated with allantoin. Moreover, in anesthetized rats, allantoin inhibited cardiac contractility and heart rate as showing in hemodynamic dP/dt max significantly. Also, the peripheral blood flow was markedly increased by allantoin. Both actions were diminished by efaroxan at the dose sufficient to block I-1R. Thus, we suggest that allantoin, as I-1R agonist, has the potential to develop as a new therapeutic agent for hypertension in the future.

Figures
Products